Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Solid Biosciences Inc. (SLDB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.5459+0.0085 (+1.58%)
At close: 04:00PM EDT
0.5500 +0.00 (+0.75%)
After hours: 05:09PM EDT
Advertisement

Solid Biosciences Inc.

141 Portland Street
Fifth Floor
Cambridge, MA 02139
United States
617 337 4680
https://www.solidbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees104

Key Executives

NameTitlePayExercisedYear Born
Mr. Ian F. Smith A.C.A., ACA, C.P.A., CPAExec. Chair72.73kN/A1966
Mr. Ilan GanotCo-founder, Pres, CEO & Director749.03kN/A1974
Mr. Matthew Bennett ArnoldCo-Founder & Board Member19.45kN/A1970
Dr. Joel Solomon Zev Schneider Ph.D.Chief Operating Officer547.71kN/A1985
Ms. Erin Powers BrennanChief Legal Officer & Sec.495.99kN/A1971
Mr. Gilad David HayeemCo-FounderN/AN/A1968
Ms. Annie GanotCo-Founder & Head of Patient AdvocacyN/AN/AN/A
Dr. Andrey Juan Zarur Ph.D.Co-FounderN/AN/A1971
Mr. Stephen J. DiPalma M.B.A.Interim CFO, Treasurer & Principal Accounting OfficerN/AN/A1959
Dr. Carl Ashley Morris Ph.D.Chief Scientific OfficerN/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Solid Biosciences Inc.’s ISS Governance QualityScore as of May 1, 2022 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement